MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Department of Population Health, The London School of Hygiene and Tropical Medicine, London, UK.
J Int AIDS Soc. 2022 Jan;25(1):e25861. doi: 10.1002/jia2.25861.
INTRODUCTION: Several HIV risk scores have been developed to identify individuals for prioritized HIV prevention in sub-Saharan Africa. We systematically reviewed HIV risk scores to: (1) identify factors that consistently predicted incident HIV infection, (2) review inclusion of community-level HIV risk in predictive models and (3) examine predictive performance. METHODS: We searched nine databases from inception until 15 February 2021 for studies developing and/or validating HIV risk scores among the heterosexual adult population in sub-Saharan Africa. Studies not prospectively observing seroconversion or recruiting only key populations were excluded. Record screening, data extraction and critical appraisal were conducted in duplicate. We used random-effects meta-analysis to summarize hazard ratios and the area under the receiver-operating characteristic curve (AUC-ROC). RESULTS: From 1563 initial search records, we identified 14 risk scores in 13 studies. Seven studies were among sexually active women using contraceptives enrolled in randomized-controlled trials, three among adolescent girls and young women (AGYW) and three among cohorts enrolling both men and women. Consistently identified HIV prognostic factors among women were younger age (pooled adjusted hazard ratio: 1.62 [95% confidence interval: 1.17, 2.23], compared to above 25), single/not cohabiting with primary partners (2.33 [1.73, 3.13]) and having sexually transmitted infections (STIs) at baseline (HSV-2: 1.67 [1.34, 2.09]; curable STIs: 1.45 [1.17; 1.79]). Among AGYW, only STIs were consistently associated with higher incidence, but studies were limited (n = 3). Community-level HIV prevalence or unsuppressed viral load strongly predicted incidence but was only considered in 3 of 11 multi-site studies. The AUC-ROC ranged from 0.56 to 0.79 on the model development sets. Only the VOICE score was externally validated by multiple studies, with pooled AUC-ROC 0.626 [0.588, 0.663] (I : 64.02%). CONCLUSIONS: Younger age, non-cohabiting and recent STIs were consistently identified as predicting future HIV infection. Both community HIV burden and individual factors should be considered to quantify HIV risk. However, HIV risk scores had only low-to-moderate discriminatory ability and uncertain generalizability, limiting their programmatic utility. Further evidence on the relative value of specific risk factors, studies populations not restricted to "at-risk" individuals and data outside South Africa will improve the evidence base for risk differentiation in HIV prevention programmes. PROSPERO NUMBER: CRD42021236367.
简介:为了确定撒哈拉以南非洲地区需要优先进行艾滋病毒预防的人群,已经开发出了几种艾滋病毒风险评分。我们系统地回顾了艾滋病毒风险评分,以:(1)确定一致预测艾滋病毒感染的因素,(2)审查预测模型中纳入社区层面艾滋病毒风险的情况,以及(3)评估预测性能。
方法:我们从九个数据库中检索了从成立到 2021 年 2 月 15 日的研究,这些研究旨在开发和/或验证撒哈拉以南非洲地区异性恋成年人群中的艾滋病毒风险评分。不前瞻性观察血清转换或仅招募关键人群的研究被排除在外。记录筛选、数据提取和关键评估都是由两人进行的。我们使用随机效应荟萃分析来总结风险比和接收者操作特征曲线下的面积(AUC-ROC)。
结果:从 1563 个初始搜索记录中,我们确定了 13 项研究中的 14 项风险评分。7 项研究针对使用避孕药具的性活跃女性进行了随机对照试验,3 项研究针对青少年女孩和年轻女性(AGYW)进行了研究,3 项研究针对同时招募男性和女性的队列进行了研究。女性中一致确定的艾滋病毒预后因素包括年龄较小(合并调整后的危险比:1.62 [95%置信区间:1.17,2.23],与 25 岁以上相比)、未婚/与主要伴侣不同居(2.33 [1.73,3.13])和基线时患有性传播感染(STIs)(HSV-2:1.67 [1.34,2.09];可治愈的 STIs:1.45 [1.17;1.79])。在 AGYW 中,只有 STIs 与更高的发病率相关,但研究有限(n=3)。社区层面的艾滋病毒流行率或未抑制的病毒载量强烈预测发病率,但仅在 11 项多地点研究中的 3 项中进行了考虑。AUC-ROC 在模型开发集中的范围为 0.56 至 0.79。只有 VOICE 评分被多项研究进行了外部验证,汇总 AUC-ROC 为 0.626 [0.588,0.663](I :64.02%)。
结论:年龄较小、非同居和最近的 STIs 被一致确定为预测未来 HIV 感染的因素。应考虑社区艾滋病毒负担和个体因素来量化 HIV 风险。然而,HIV 风险评分的区分能力较低,适用性不确定,限制了其在方案中的实用性。关于特定风险因素的相对价值、不限于“高危”人群的研究人群以及南非以外的数据的进一步证据将改善 HIV 预防方案中风险分层的证据基础。
PROSPERO 编号:CRD42021236367。
Cochrane Database Syst Rev. 2004
Cochrane Database Syst Rev. 2006-7-19
Cochrane Database Syst Rev. 2001
Cochrane Database Syst Rev. 2003
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2022-5-20
Cochrane Database Syst Rev. 2007-1-24
Cochrane Database Syst Rev. 2018-1-22
Cochrane Database Syst Rev. 2025-6-6
Nat Med. 2025-3
J Acquir Immune Defic Syndr. 2020-10-1
Evid Based Ment Health. 2019-9-28